Chiltern Finalizes Acquisition of Theorem Clinical Research

LONDON & WILMINGTON, N.C.--()--Chiltern, a leading global contract research organization (CRO), has completed its acquisition of Theorem Clinical Research, strengthening its position as the largest mid-sized provider of comprehensive, yet flexible and responsive, clinical development services.

Chiltern now comprises 3,700 people across 47 countries, expanding Chiltern's footprint in Europe, North America and Asia-Pacific. The acquisition enhances Chiltern's OncologyBiopharma and Source offerings, broadens its therapeutic expertise and establishes new capabilities in medical device and diagnostics, clinical analytics and clinical supplies.

"By bringing Chiltern and Theorem together, we have created a unique, mid-sized research partner focused on providing exceptional scientific expertise and personal service," said Dr. Jim Esinhart, Chiltern CEO. "Clients can expect the same high level of service, now with expanded capabilities. Senior leadership will still be involved in running trials."

"The acquisition of Theorem marks an important milestone for Chiltern," said Nick Thornton, Chiltern chairman. "We stayed true to our mission to be a responsive, client-centric mid-sized provider, yet we enhanced our geographic coverage and service offerings in key areas. We are delighted to welcome the dynamic Theorem team to Chiltern and are pleased to announce thatDr. John Potthoff, Theorem's president and CEO, has joined our board as a non-executive director."

About Chiltern:

Chiltern is the leading, global mid-sized contract research organization that listens to client needs to deliver customized clinical development solutions. Chiltern's team of more than 3,700 works across 47 countries to provide flexible, specialized services, with core competencies in Biopharma, Medical Device and Diagnostics, Oncology, Clinical Analytics and Source. VisitChiltern.com to learn more about responsive solutions that are Designed Around You®.

Chiltern was advised by Jefferies LLC, Hughes Hubbard & Reed LLP, Simmons & Simmons LLP and Deloitte LLP, London. Theorem was advised by Robert W. Baird & Co. and Goodwin Procter LLP.

 

Contacts

SCORR Marketing
Lea Studer, 308-237-5567
[email protected]

 

Suggested Articles

Dr. Ian Hudson is stepping down after six years in charge of the Medicines and Healthcare products Regulatory Agency next month.

Oncology tests in the U.S. are still failing to adequately represent racial diversity, and more needs to be done to help combat this disparity.

Symphony Health has inked a new deal with Close-Up International aimed at boosting its global data services.